Genocea Revenue and Competitors
Estimated Revenue & Valuation
- Genocea's estimated annual revenue is currently $18.9M per year.
- Genocea received $55.0M in venture funding in January 2018.
- Genocea's estimated revenue per employee is $155,000
- Genocea's total funding is $470.6M.
Employee Data
- Genocea has 122 Employees.
- Genocea grew their employee count by -21% last year.
Genocea's People
| Name | Title | Email/Phone |
|---|
Genocea Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Genocea?
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus.
keywords:Biotechnology,Enterprise Software,Healthcare,Pharmaceuticals
$470.6M
Total Funding
122
Number of Employees
$18.9M
Revenue (est)
-21%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Genocea News
Genocea Biosciences (NASDAQ:GNCA) has initiated a process to explore a range of strategic alternatives to maximize shareholder value,...
Genocea's mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer.
GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues Strong presence at the SITC 36th Annual Meeting Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., October 28, 2021 - Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-gen ...
GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues GEN-009 neoantigen vaccine candidate shows promising long-term clinical results Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), ...
GEN-011 and GEN-009 immuno-oncology programs continue to advance Research on Inhibigens™ and SARS-CoV-2 continues to progress Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company deve ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $24.5M | 122 | 6% | N/A |
#2 | $31M | 122 | N/A | N/A |
#3 | $17.1M | 122 | 18% | N/A |
#4 | $22M | 123 | 1% | $478.3M |
#5 | $30.3M | 123 | 31% | N/A |
Genocea Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2009-02-20 | $23.0M | A | SR One | Article |
| 2011-01-04 | $35.0M | Second | Johnson & Johnson Development , Skyline Ventures | Article |
| 2012-10-11 | $30.0M | C | The Bill & Melinda Gates Found, CVF LLC | Article |
| 2013-10-16 | $0.4M | Undisclosed | Article | |
| 2014-11-24 | $27.0M | Undisclosed | Hercules Technology Growth Capital | Article |
| 2015-03-13 | $51.7M | Undisclosed | Cowen and Company | Article |
| 2015-07-31 | $57.6M | Undisclosed | Multiple | Article |
| 2018-01-18 | $55.0M | Undisclosed | Cantor Fitzgerald & Co | Article |